The cleanup crew, restarted

Retro Biosciences, the longevity company Sam Altman seeded with $180M of his own money, announced in May that a new investor — 4P Capital — had led a priced round valuing it at $1.8 billion before the new money. Worth saying plainly, because most of the coverage got it wrong: that $1.8B is a pre-money valuation, not the amount raised. Retro pointedly never disclosed how much it actually took in, and the widely repeated '$1B raise' is a target it floated back in January 2025, not a closed round. (For scale, Altos Labs raised an actual $3B in a single 2022 round.)

Retro never disclosed how much it raised; Altos Labs put $3B on the table in a single round — and longevity's graveyard is full of well-funded autophagy bets that human data never rewarded.

The number is not the story; the drug behind it is. Retro is known as a cellular-reprogramming bet — the science of rewinding a cell's biological age — but its lead clinical asset does something far more modest. RTR242 is an oral pill that restarts autophagy, a cell's internal recycling system that clogs and slows with age. It works by re-acidifying the lysosome, the cell's acid bath where worn-out proteins are dissolved; when that bath loses its acidity, the garbage piles up. The drug restores the pH so the cleanup crew can get back to work.

That mechanism is the genuinely differentiated angle, and it moved fast: from picking a disease to dosing the first human in fifteen months. The Phase 1 trial, running in Australia, targets Alzheimer's, where the failure to clear protein aggregates is a leading suspect. It is a safety trial in a small cohort with no efficacy data; first readouts are expected around August. Whether re-acidified lysosomes translate into slowed aging — or even a dented Alzheimer's — is, for now, a hypothesis with a valuation attached.